Stephens Inc. AR Boosts Position in AbbVie Inc. $ABBV

Stephens Inc. AR raised its stake in AbbVie Inc. (NYSE:ABBV) by 4.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 150,987 shares of the company’s stock after purchasing an additional 5,969 shares during the period. Stephens Inc. AR’s holdings in AbbVie were worth $34,960,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its position in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares during the period. First Hawaiian Bank boosted its holdings in shares of AbbVie by 0.8% in the second quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock valued at $1,403,000 after acquiring an additional 60 shares during the period. Gallacher Capital Management LLC grew its position in shares of AbbVie by 117.7% during the second quarter. Gallacher Capital Management LLC now owns 2,356 shares of the company’s stock worth $437,000 after acquiring an additional 1,274 shares during the last quarter. Finally, Apella Capital LLC increased its holdings in shares of AbbVie by 3.9% in the 2nd quarter. Apella Capital LLC now owns 9,170 shares of the company’s stock valued at $1,721,000 after acquiring an additional 343 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a three‑year voluntary agreement with the U.S. administration that exempts the company from tariffs and future pricing mandates while committing to major U.S. investment — a headline that reduces policy/regulatory uncertainty and signals long‑term U.S. capital deployment. Read More.
• Positive Sentiment: AbbVie signed an exclusive global licensing deal (up to ~$5.6B) with RemeGen for RC148, a PD‑1/VEGF bispecific — this meaningfully expands AbbVie’s oncology pipeline and long‑term growth optionality. Read More.
• Positive Sentiment: AbbVie is buying a drug‑delivery system and Arizona manufacturing facility from West Pharmaceutical and is investing in U.S. manufacturing (including a reported $175M plant spend) — supports supply chain control and the company’s U.S. investment pledge. Read More.
• Neutral Sentiment: AbbVie joined peers in urging FDA updates to post‑approval change rules — could improve manufacturing flexibility but is a regulatory/industry‑wide request with uncertain timing. Read More.
• Neutral Sentiment: A Phase 2 bipolar depression study (ABBV‑932) reached completion — a development milestone that requires readouts for directional impact. Read More.
• Negative Sentiment: Under the U.S. deal AbbVie agreed to provide lower prices in Medicaid (and expand affordable offerings) — a meaningful concession that could weigh on near‑term revenue and margins for affected products. Read More.

AbbVie Trading Up 0.2%

Shares of ABBV stock opened at $220.51 on Wednesday. The stock has a 50 day simple moving average of $226.84 and a 200-day simple moving average of $216.04. The company has a market cap of $389.72 billion, a price-to-earnings ratio of 167.05, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 496.97%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ABBV. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and increased their price target for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. UBS Group reiterated a “neutral” rating on shares of AbbVie in a research note on Tuesday. Piper Sandler reissued an “overweight” rating and set a $289.00 price target (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Finally, Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.